Head and neck cancer, the fifth most common cancer based on MOHW 2011 report in Taiwan, has suboptimal treatment response rates. Recently literatures suggest that Neurotensin receptor 1 plays a very important role in cancer progression and overall survival of patients. To provide a novel therapeutic modality for cancer therapy, DCB and NHRI have developed an anti NTSR1 antibody drug conjugate DCBAD2301 with high specificity, potent tumor suppression, favorable PK, and low toxicity in vitro and in vivo. With a high-yield CHO cell line, DCBAD2301 offers innovative potential for cancer therapy.
With over 400 dedicated researchers and state-of-the-art facilities , the Development Center for Biotechnology (DCB) specializes in developing biologics and small molecule drugs , botanical drugs , as well as technologies required for preclinical testing. Our expertise arises from the integration of a number of diverse disciplines , including biology , chemistry , protein purification and engineering , as well as analytical and quality assurance. Established in 1984 by Taiwan's Ministry of Economic Affairs (MOEA) , Department of Industrial Technology (DoIT) , DCB was initially tasked with establishing the biotechnology industry in Taiwan. Through strategic global alliances and technology transfer agreements , DCB has successfully fostered the development of a complete biotech infrastructure and value chain , as well as a diverse array of applications for use by the private sector. As a result , DCB has become one of Taiwan's most important research institutes. DCB's mission is to facilitate the ongoing growth and development Taiwan's biotechnology industry. To this end , we strive to act as the industry's partner , coordinating resources among government , academia and private companies. DCB remains a key force in building and upgrading Taiwan's biomedical infrastructure, developing key technologies , and growing Taiwan's professional workforce. Our ultimate aim is to improve the quality of life for the people of Taiwan and the world. To this end , DCB fosters international partnerships and collaborations with research institutes and global biopharmaceuticals throughout Asia and the world.
Name:Cheng-Chou Yu
Phone:(02)7700-3800#5403
Address:No.107, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan, R.O.C.
A Wearable and Self-powered Multifunctional Module for Active Infectio n Prevention, Accelerated Wound Healing and Noninvasive Healing Moni toring
Novel Therapeutic Approach for Castration Resistant Prostate Cancer
Targeted extracellular vesicle-based therapeutic platform: A nanocarrier for nucleic acid and chemotherapeutic drug delivery
Novel cancer immunotherapeutic agent targeting tumor and tumor immune microenvironment for the treatment of triple negative breast cancer
Technology maturity:Mass production
Exhibiting purpose:Technology transactions
Trading preferences:Exclusive license/assignment
*Organization
*Name
*Phone
*Main Purpose
*Discuss Further
*Job Category
*Overall Rating
*Favorite Area
*Key Tech Focus
*Willing to Receive Updates?
Other Suggestions
Coming soon!